ArticleFrontiers in molecular biosciences2026
Protein oxidation, glycation, and carbamylation in patients with adrenal masses.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adrenal masses are the most common of all tumors in the adult population, and their size is associated with malignancy. The knowledge about the pathogenesis of adrenal tumors is limited. Objectives: Evaluation of the association between protein glycooxidation and carbamylation, as well as thiol-disulfide homeostasis and adrenal tumor size. The study group included 71 patients (39 women and 32 men) with adrenal masses, divided into two groups: 34 patients with adrenal masses <4 cm in diameter and 37 patients with adrenal masses >4 cm in diameter. Colorimetric and spectrophotometric methods were used in this study. The protein oxidative damage (increase in ischemia-modified albumin) and glycooxidation rate (increase in kynurenine, dityrosine, Amadori products, advanced glycation end products, and carbamyl-lysine [CBL]) were significantly higher in patients with adrenal masses than in comparison with the control group. Additionally, thiol-disulfide homeostasis (decrease in total thiols and native thiols and increase in disulfide) was disturbed in these patients. The plasma content of CBL seemed to express possible diagnostic utility. This parameter, with 75.68% sensitivity and 74% specificity, differentiates patients with adrenal tumors (both AM < 4 cm and AM > 4 cm) from the controls. Moreover, plasma content of CBL has a diagnostic value in distinguishing AM < 4 cm from those AM > 4 cm. In conclusion, protein glycoxidation and thiol-disulfide homeostasis are impaired in patients with adrenal tumors. Although oxidative stress is involved in the progression of carcinogenesis, oxidation and glycoxidation of plasma proteins, as well as thiol-disulfide homeostasis, were not dependent on tumor size. Only the evaluation of CBL plasma content seems helpful in predicting the malignant risk of adrenal masses. More research is needed to confirm our results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.